What’s the difference between synthetic and bioidentical peptides?

“Synthetic” describes manufacture; “bioidentical” is generally used to mean that a molecule matches one naturally made by the body. These are not necessarily opposites: a laboratory can make a molecule with the same amino-acid sequence and structure as a human peptide. Conversely, a medicine can be deliberately modified so it is no longer identical to the native hormone. Neither word, on its own, establishes clinical safety.[1][2]

Semaglutide illustrates why modification can be useful. It is an analog of GLP-1 with changes that make it resist breakdown and remain in circulation much longer than native GLP-1. Those changes support a different exposure pattern and clinical use. Calling an analog “unnatural” does not establish harm, just as calling a preparation “bioidentical” does not establish that its dose, duration of exposure, or formulation is appropriate.[1]

When comparing products, ask whether the structure and biological activity have been verified, how the drug is delivered, and what human outcomes and adverse effects have been studied. Manufacturing quality and impurities remain relevant even when the intended sequence matches a human molecule. FDA also cautions against treating “bioidentical” hormone marketing as evidence that compounded products are safer than approved medicines.[2][3]